Clinical trial
A Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension
NCT02223481 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 1998
- Completion date
- Not reported
- Enrollment
- 71 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.